Please login to the form below

Not currently logged in
Email:
Password:

Depomed and Watson sign co-promotion deal

Depomed and Watson Pharmaceuticals have entered into a co-promotion agreement for ProQuin XR, Depomed's extended-release formulation of ciprofloxacin for the treatment of uncomplicated urinary tract infections.

Depomed and Watson Pharmaceuticals have entered into a co-promotion agreement for ProQuin XR, Depomed's extended-release formulation of ciprofloxacin for the treatment of uncomplicated urinary tract infections.

Under the agreement, Depomed has granted Watson a co-exclusive right to promote ProQuin XR for the urology and long-term care specialties in the US and its possessions, including Puerto Rico.

Per the agreement, Depomed will book top-line revenue and Watson will receive a portion of the profits. Watson and Depomed plan to re-launch ProQuin XR in the US urology market by the end of this year.

Depomed retains manufacturing and distribution rights and Watson will be responsible for promotion to physicians in urology and long-term care.

Extended release versions of ciprofloxacin are also sold by Germany-based Bayer and Indian pharmaceutical company Ranbaxy.

According to a Market Research report, fluoroquinolone sales are expected to remain relatively constant to 2011. The fluoroquinolone market is heavily dominated by ciprofloxacin and levofloxacin, which together command 65 per cent (USD 3.3bn) of global sales.

25th July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics